

Stuart J Peacock

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6340367/publications.pdf>

Version: 2024-02-01

171
papers

5,086
citations

109321

35
h-index

118850

62
g-index

176
all docs

176
docs citations

176
times ranked

6768
citing authors

#	ARTICLE	IF	CITATIONS
1	Multiple Criteria Decision Analysis for Health Care Decision Making—An Introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force. <i>Value in Health</i> , 2016, 19, 1-13.	0.3	437
2	Multiple Criteria Decision Analysis for Health Care Decision Making—Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force. <i>Value in Health</i> , 2016, 19, 125-137.	0.3	320
3	Public participation in health care priority setting: A scoping review. <i>Health Policy</i> , 2009, 91, 219-228.	3.0	283
4	Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months. <i>JAMA - Journal of the American Medical Association</i> , 2018, 320, 43.	7.4	190
5	Participant selection for lung cancer screening by risk modelling (the Pan-Canadian Early Detection) Tj ETQq1 1 0.784314 rgBT /Overl 1523-1531.	10.7	158
6	Construction of the descriptive system for the assessment of quality of life AQoL-6D utility instrument. <i>Health and Quality of Life Outcomes</i> , 2012, 10, 38.	2.4	124
7	The Cost-Effectiveness of High-Risk Lung Cancer Screening and Drivers of Program Efficiency. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1210-1222.	1.1	112
8	Vision and Quality of Life: The Development of a Utility Measure. , 2005, 46, 4007.		85
9	Understanding the costs of cancer care before and after diagnosis for the 21 most common cancers in Ontario: a population-based descriptive study. <i>CMAJ Open</i> , 2013, 1, E1-E8.	2.4	85
10	Measurement of the Quality of Life for Economic Evaluation and the Assessment of Quality of Life (AQoL) Mark 2 Instrument. <i>Australian Economic Review</i> , 2004, 37, 62-88.	0.7	84
11	Using economics to set pragmatic and ethical priorities. <i>BMJ: British Medical Journal</i> , 2006, 332, 482-485.	2.3	84
12	The economic burden of cancer care in Canada: a population-based cost study. <i>CMAJ Open</i> , 2018, 6, E1-E10.	2.4	79
13	Australian Utility Weights for the EORTC QLU-C10D, a Multi-Attribute Utility Instrument Derived from the Cancer-Specific Quality of Life Questionnaire, EORTC QLQ-C30. <i>Pharmacoeconomics</i> , 2018, 36, 225-238.	3.3	77
14	Societal preferences for the return of incidental findings from clinical genomic sequencing: a discrete-choice experiment. <i>Cmaj</i> , 2015, 187, E190-E197.	2.0	76
15	Overcoming barriers to priority setting using interdisciplinary methods. <i>Health Policy</i> , 2009, 92, 124-132.	3.0	75
16	Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial — the HPV FOCAL Study. <i>British Journal of Cancer</i> , 2012, 107, 1917-1924.	6.4	71
17	Phase-specific and lifetime costs of cancer care in Ontario, Canada. <i>BMC Cancer</i> , 2016, 16, 809.	2.6	71
18	HPV for cervical cancer screening (HPV FOCAL): Complete Round 1 results of a randomized trial comparing HPV-based primary screening to liquid-based cytology for cervical cancer. <i>International Journal of Cancer</i> , 2017, 140, 440-448.	5.1	70

#	ARTICLE	IF	CITATIONS
19	A randomized controlled trial of Human Papillomavirus (HPV) testing for cervical cancer screening: trial design and preliminary results (HPV FOCAL Trial). <i>BMC Cancer</i> , 2010, 10, 111.	2.6	68
20	Health care costs associated with hepatocellular carcinoma: A population-based study. <i>Hepatology</i> , 2013, 58, 1375-1384.	7.3	64
21	“Real-world” health care priority setting using explicit decision criteria: a systematic review of the literature. <i>BMC Health Services Research</i> , 2015, 15, 164.	2.2	58
22	Using a discrete choice experiment to value the QLU-C10D: feasibility and sensitivity to presentation format. <i>Quality of Life Research</i> , 2016, 25, 637-649.	3.1	58
23	Priority setting in health care using multi-attribute utility theory and programme budgeting and marginal analysis (PBMA). <i>Social Science and Medicine</i> , 2007, 64, 897-910.	3.8	54
24	A prospective clinical utility and pharmacoeconomic study of the impact of the 21-gene Recurrence Score [®] assay in oestrogen receptor positive node negative breast cancer. <i>European Journal of Cancer</i> , 2013, 49, 2469-2475.	2.8	50
25	The ability of cancer-specific and generic preference-based instruments to discriminate across clinical and self-reported measures of cancer severities. <i>Health and Quality of Life Outcomes</i> , 2011, 9, 106.	2.4	48
26	Cost-effectiveness of MRI for breast cancer screening in BRCA1/2 mutation carriers. <i>BMC Cancer</i> , 2013, 13, 339.	2.6	47
27	Vision and Quality of Life: Development of Methods for the VisQoL Vision-Related Utility Instrument. <i>Ophthalmic Epidemiology</i> , 2008, 15, 218-223.	1.7	46
28	Resource Utilization and Costs during the Initial Years of Lung Cancer Screening with Computed Tomography in Canada. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1449-1458.	1.1	45
29	Moral Distress Among Health System Managers: Exploratory Research in Two British Columbia Health Authorities. <i>Health Care Analysis</i> , 2011, 19, 107-121.	2.2	44
30	Assessing the Real-World Cost-Effectiveness of Adjuvant Trastuzumab in HER2/neu Positive Breast Cancer. <i>Oncologist</i> , 2012, 17, 164-171.	3.7	44
31	Conducting clinical trials—costs, impacts, and the value of clinical trials networks: A scoping review. <i>Clinical Trials</i> , 2019, 16, 183-193.	1.6	42
32	Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: a population-based analysis. <i>BMC Cancer</i> , 2014, 14, 586.	2.6	41
33	Mapping the FACT-G cancer-specific quality of life instrument to the EQ-5D and SF-6D. <i>Health and Quality of Life Outcomes</i> , 2013, 11, 203.	2.4	40
34	Is prostate cancer screening cost-effective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, Canada. <i>International Journal of Cancer</i> , 2014, 135, 939-947.	5.1	39
35	Supplier-Induced Demand. <i>Applied Health Economics and Health Policy</i> , 2006, 5, 87-98.	2.1	37
36	Trends in use and cost of initial cancer treatment in Ontario: a population-based descriptive study. <i>CMAJ Open</i> , 2013, 1, E151-E158.	2.4	37

#	ARTICLE	IF	CITATIONS
37	Cervical screening during the COVID-19 pandemic: optimising recovery strategies. <i>Lancet Public Health</i> , 2021, 6, e522-e527.	10.0	37
38	Identifying research priorities for health care priority setting: a collaborative effort between managers and researchers. <i>BMC Health Services Research</i> , 2009, 9, 165.	2.2	36
39	Childhood, adolescent, and young adult cancer survivors research program of British Columbia: Objectives, study design, and cohort characteristics. <i>Pediatric Blood and Cancer</i> , 2010, 55, 324-330.	1.5	36
40	Influence of Socioeconomic Status on Survival of Hepatocellular Carcinoma in the Ontario Population; A Population-Based Study, 1990-2009. <i>PLoS ONE</i> , 2012, 7, e40917.	2.5	36
41	A Time-Trend Economic Analysis of Cancer Drug Trials. <i>Oncologist</i> , 2015, 20, 729-736.	3.7	35
42	Health-related quality of life and anxiety in the PAN-CAN lung cancer screening cohort. <i>BMJ Open</i> , 2019, 9, e024719.	1.9	32
43	Priority setting in healthcare: towards guidelines for the program budgeting and marginal analysis framework. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2010, 10, 539-552.	1.4	30
44	HEALTH TECHNOLOGY ASSESSMENT AND PERSONALIZED MEDICINE: ARE ECONOMIC EVALUATION GUIDELINES SUFFICIENT TO SUPPORT DECISION MAKING?. <i>International Journal of Technology Assessment in Health Care</i> , 2014, 30, 179-187.	0.5	30
45	Plasma pro-surfactant protein B and lung function decline in smokers. <i>European Respiratory Journal</i> , 2015, 45, 1037-1045.	6.7	30
46	Evaluation of New Tests and Interventions for Prostate Cancer Management: A Systematic Review. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 1340-1351.	4.9	30
47	Genomic testing to determine drug response: measuring preferences of the public and patients using Discrete Choice Experiment (DCE). <i>BMC Health Services Research</i> , 2013, 13, 454.	2.2	28
48	How Procurement Judges The Value of Medical Technologies: A Review of Healthcare Tenders. <i>International Journal of Technology Assessment in Health Care</i> , 2019, 35, 50-55.	0.5	26
49	Priority setting in practice: what is the best way to compare costs and benefits?. <i>Health Economics (United Kingdom)</i> , 2009, 18, 467-478.	1.7	25
50	Cost-Effectiveness of the Addition of Rituximab to CHOP Chemotherapy in First-Line Treatment for Diffuse Large B-Cell Lymphoma in a Population-Based Observational Cohort in British Columbia, Canada. <i>Value in Health</i> , 2010, 13, 703-711.	0.3	25
51	Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis. <i>Journal of Thoracic Oncology</i> , 2011, 6, 2097-2103.	1.1	25
52	Effect of Early Palliative Care on End-of-Life Health Care Costs: A Population-Based, Propensity Score-Matched Cohort Study. <i>JCO Oncology Practice</i> , 2022, 18, e183-e192.	2.9	25
53	Mapping utilities from cancer-specific health-related quality of life instruments: a review of the literature. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2013, 13, 753-765.	1.4	24
54	Introducing Priority Setting and Resource Allocation in Home and Community Care Programs. <i>Journal of Health Services Research and Policy</i> , 2008, 13, 41-45.	1.7	23

#	ARTICLE	IF	CITATIONS
55	Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: A real-world cost-effectiveness analysis. <i>Lung Cancer</i> , 2012, 76, 472-477.	2.0	23
56	Long-term cardiovascular outcomes and overall survival of early-stage breast cancer patients with early discontinuation of trastuzumab: a population-based study. <i>Breast Cancer Research and Treatment</i> , 2016, 157, 535-544.	2.5	23
57	High performance in healthcare priority setting and resource allocation: A literature- and case study-based framework in the Canadian context. <i>Social Science and Medicine</i> , 2016, 162, 185-192.	3.8	23
58	Supplier-induced demand: re-examining identification and misspecification in cross-sectional analysis. <i>European Journal of Health Economics</i> , 2007, 8, 267-277.	2.8	22
59	Qualitative methodologies in health care priority setting research. <i>Health Economics (United Kingdom)</i> 1 0.784314, 17, 19-21.	1.7	21
60	Moral Distress among Healthcare Managers: Conditions, Consequences and Potential Responses. <i>Healthcare Policy</i> , 2010, 6, 99-112.	0.6	20
61	Access to Cancer Drugs in Canada: Looking Beyond Coverage Decisions. <i>Healthcare Policy</i> , 2011, 6, 27-35.	0.6	20
62	Decision maker perceptions of resource allocation processes in Canadian health care organizations: a national survey. <i>BMC Health Services Research</i> , 2013, 13, 247.	2.2	20
63	Public engagement in priority-setting: Results from a pan-Canadian survey of decision-makers in cancer control. <i>Social Science and Medicine</i> , 2014, 122, 130-139.	3.8	20
64	Temporal changes in treatments and outcomes after acute myocardial infarction among cancer survivors and patients without cancer, 1995 to 2013. <i>Cancer</i> , 2018, 124, 1269-1278.	4.1	20
65	Population-Based Trends in Systemic Therapy Use and Cost for Cancer Patients in the Last Year of Life. <i>Current Oncology</i> , 2016, 23, 32-41.	2.2	19
66	Health Technology Assessment as Part of a Broader Process for Priority Setting and Resource Allocation. <i>Applied Health Economics and Health Policy</i> , 2019, 17, 573-576.	2.1	19
67	Estimating the Cost of Cancer Care in British Columbia and Ontario: A Canadian Inter-Provincial Comparison. <i>Healthcare Policy</i> , 2017, 12, 95-108.	0.6	19
68	Using PBMA in health care priority setting: description, challenges and experience. <i>Applied Health Economics and Health Policy</i> , 2003, 2, 121-7.	2.1	19
69	Integrating public input into healthcare priority-setting decisions. <i>Evidence and Policy</i> , 2011, 7, 327-343.	1.0	18
70	Incremental cost-effectiveness of the pre- and post-bevacizumab eras of metastatic colorectal cancer therapy in British Columbia, Canada. <i>European Journal of Cancer</i> , 2012, 48, 1969-1976.	2.8	18
71	Addressing the affordability of cancer drugs: using deliberative public engagement to inform health policy. <i>Health Research Policy and Systems</i> , 2019, 17, 17.	2.8	18
72	Understanding cancer survivors' reasons to medicate with cannabis: A qualitative study based on the theory of planned behavior. <i>Cancer Medicine</i> , 2021, 10, 396-404.	2.8	18

#	ARTICLE	IF	CITATIONS
73	A New Formula for Distributing Hospital Funds in England. <i>Interfaces</i> , 1997, 27, 53-70.	1.5	17
74	Capitation funding in Australia: imperatives and impediments. <i>Health Care Management Science</i> , 2000, 3, 77-88.	2.6	17
75	Utility Weights for the Vision-related Assessment of Quality of Life (AQoL)-7D Instrument. <i>Ophthalmic Epidemiology</i> , 2012, 19, 172-182.	1.7	17
76	Cost-effectiveness of annual versus biennial screening mammography for women with high mammographic breast density. <i>Journal of Medical Screening</i> , 2014, 21, 180-188.	2.3	17
77	Cost-Effectiveness Analysis of Using Loss of Heterozygosity to Manage Premalignant Oral Dysplasia in British Columbia, Canada. <i>Oncologist</i> , 2016, 21, 1099-1106.	3.7	17
78	A discrete choice experiment of preferences for genetic counselling among Jewish women seeking cancer genetics services. <i>British Journal of Cancer</i> , 2006, 95, 1448-1453.	6.4	16
79	Severity as an independent determinant of the social value of a health service. <i>European Journal of Health Economics</i> , 2011, 12, 163-174.	2.8	16
80	Long-term effects of cancer on earnings of childhood, adolescent and young adult cancer survivors â€” a population-based study from British Columbia, Canada. <i>BMC Health Services Research</i> , 2018, 18, 826.	2.2	16
81	Trade-offs, fairness, and funding for cancer drugs: key findings from a deliberative public engagement event in British Columbia, Canada. <i>BMC Health Services Research</i> , 2018, 18, 339.	2.2	16
82	The EORTC QLU-C10D: The Canadian Valuation Study and Algorithm to Derive Cancer-Specific Utilities From the EORTC QLQ-C30. <i>MDM Policy and Practice</i> , 2019, 4, 238146831984253.	0.9	16
83	Health-related quality of life in oncology drug reimbursement submissions in Canada: A review of submissions to the pan-Canadian Oncology Drug Review. <i>Cancer</i> , 2020, 126, 148-155.	4.1	16
84	Do quality-adjusted life years take account of lost income? Evidence from an Australian survey. <i>European Journal of Health Economics</i> , 2009, 10, 103-109.	2.8	15
85	End-of-life outcomes with or without early palliative care: a propensity score matched, population-based cancer cohort study. <i>BMJ Open</i> , 2021, 11, e041432.	1.9	15
86	Moral Distress among Healthcare Managers: Conditions, Consequences and Potential Responses. <i>Healthcare Policy</i> , 2010, 6, 99-112.	0.6	15
87	Guidelines for Health Technologies: Specific Guidance for Oncology Products in Canada. <i>Value in Health</i> , 2012, 15, 580-585.	0.3	14
88	Trajectory of psychosocial symptoms among home care patients with cancer at end-of-life. <i>Psycho-Oncology</i> , 2021, 30, 103-110.	2.3	14
89	Assessing 10-Year Safety of a Single Negative HPV Test for Cervical Cancer Screening: Evidence from FOCAL-DECADE Cohort. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 22-29.	2.5	14
90	The Functional Assessment of Cancer Therapy Eight Dimension (FACT-8D), a Multi-Attribute Utility Instrument Derived From the Cancer-Specific FACT-General (FACT-G) Quality of Life Questionnaire: Development and Australian Value Set. <i>Value in Health</i> , 2021, 24, 862-873.	0.3	14

#	ARTICLE	IF	CITATIONS
91	Strengths and limitations of competitive versus non-competitive models of integrated capitated fundholding. <i>Journal of Health Services Research and Policy</i> , 2002, 7, 56-64.	1.7	13
92	Value assessment of oncology drugs using a weighted criterion-based approach. <i>Cancer</i> , 2020, 126, 1530-1540.	4.1	13
93	Verification of imatinib cost-effectiveness in advanced gastrointestinal stromal tumor in British Columbia (VINCE-BC study). <i>Journal of Oncology Pharmacy Practice</i> , 2008, 14, 105-112.	0.9	12
94	Using evaluation theory in priority setting and resource allocation. <i>Journal of Health Organization and Management</i> , 2012, 26, 655-671.	1.3	12
95	Estimating the Cost of Cancer Care in British Columbia and Ontario: A Canadian Inter-Provincial Comparison. <i>Healthcare Policy</i> , 2017, 12, 95-108.	0.6	12
96	Strengthening Medicare: will increasing the bulk-billing rate and supply of general practitioners increase access to Medicare-funded general practitioner services and does rurality matter?. <i>Australia and New Zealand Health Policy</i> , 2005, 2, 18.	2.2	11
97	Measuring, and identifying predictors of, women's perceptions of three types of breast cancer risk: population risk, absolute risk and comparative risk. <i>British Journal of Cancer</i> , 2009, 100, 583-589.	6.4	11
98	Projected Impact of HPV and LBC Primary Testing on Rates of Referral for Colposcopy in a Canadian Cervical Cancer Screening Program. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2015, 37, 412-420.	0.7	11
99	A Time-and-Motion Approach to Micro-Costing of High-Throughput Genomic Assays. <i>Current Oncology</i> , 2016, 23, 304-313.	2.2	11
100	Temporal Association between Home Nursing and Hospital Costs at End of Life in Three Provinces. <i>Current Oncology</i> , 2016, 23, 42-51.	2.2	11
101	Public perspectives on disinvestments in drug funding: results from a Canadian deliberative public engagement event on cancer drugs. <i>BMC Public Health</i> , 2019, 19, 977.	2.9	11
102	Communicating uncertainty in cancer prognosis: A review of web-based prognostic tools. <i>Patient Education and Counseling</i> , 2019, 102, 842-849.	2.2	11
103	Acceptability and Usefulness of a Dyadic, Tailored, Web-Based, Psychosocial and Physical Activity Self-Management Program (TEMPO): A Qualitative Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 3284.	2.4	11
104	Trajectory of End-of-Life Pain and Other Physical Symptoms among Cancer Patients Receiving Home Care. <i>Current Oncology</i> , 2021, 28, 1641-1651.	2.2	11
105	Canadian Colorectal Cancer Screening Guidelines: Do They Need an Update Given Changing Incidence and Global Practice Patterns?. <i>Current Oncology</i> , 2021, 28, 1558-1570.	2.2	11
106	Quality and Cost in Healthcare. <i>Applied Health Economics and Health Policy</i> , 2006, 5, 201-208.	2.1	10
107	Cost-effectiveness of rituximab in follicular lymphoma. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2012, 12, 569-577.	1.4	10
108	Economic impact of genomic diagnostics for intermediate-risk acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2016, 174, 526-535.	2.5	10

#	ARTICLE	IF	CITATIONS
109	Cost-effectiveness analysis of anal cancer screening in women with cervical neoplasia in British Columbia, Canada. <i>BMC Health Services Research</i> , 2016, 16, 206.	2.2	10
110	Disease detection and resource use in the safety and control arms of the HPV FOCAL cervical cancer screening trial. <i>British Journal of Cancer</i> , 2016, 115, 1487-1494.	6.4	10
111	Real-World Cost-Effectiveness of Bevacizumab With First-Line Combination Chemotherapy in Patients With Metastatic Colorectal Cancer: Population-Based Retrospective Cohort Studies in Three Canadian Provinces. <i>MDM Policy and Practice</i> , 2021, 6, 238146832110210.	0.9	10
112	Cost-effectiveness of therapies for melanoma. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2015, 15, 229-242.	1.4	9
113	Cost-effectiveness analysis of primary human papillomavirus testing in cervical cancer screening: Results from the HPV FOCAL Trial. <i>Cancer Medicine</i> , 2021, 10, 2996-3003.	2.8	9
114	Assessing the capacity of the health services research community in Australia and New Zealand. <i>Australia and New Zealand Health Policy</i> , 2005, 2, 4.	2.2	8
115	Determinants of Preferences for Genetic Counselling in Jewish Women. <i>Familial Cancer</i> , 2006, 5, 159-167.	1.9	8
116	Does an increase in the doctor supply reduce medical fees? An econometric analysis of medical fees across Australia. <i>Applied Economics</i> , 2006, 38, 253-266.	2.2	8
117	Social welfare and the Affordable Care Act: Is it ever optimal to set aside comparative cost?. <i>Social Science and Medicine</i> , 2012, 75, 1156-1162.	3.8	8
118	Cost-effectiveness of population-based mammography screening strategies by age range and frequency. <i>Journal of Cancer Policy</i> , 2014, 2, 97-102.	1.4	8
119	Public attitudes and values in priority setting. <i>Israel Journal of Health Policy Research</i> , 2015, 4, 29.	2.6	8
120	Theoretical Foundations of MCDA. , 2017, , 9-28.		8
121	Real-World Costing Analysis for Diffuse Large B-Cell Lymphoma in British Columbia. <i>Current Oncology</i> , 2019, 26, 108-113.	2.2	8
122	Addressing prioritization in healthcare amidst a global pandemic. <i>Healthcare Management Forum</i> , 2021, 34, 252-255.	1.4	8
123	Impact of TAILORx on chemotherapy prescribing and 21-gene recurrence score-guided treatment costs in a population-based cohort of patients with breast cancer. <i>Cancer</i> , 2022, 128, 665-674.	4.1	8
124	Cost and Resource Utilization in Cervical Cancer Management: A Real-World Retrospective Cost Analysis. <i>Current Oncology</i> , 2016, 23, 14-22.	2.2	7
125	Evidence, values, and funding decisions in Canadian cancer systems. <i>Healthcare Management Forum</i> , 2019, 32, 293-298.	1.4	7
126	Uncertainty tolerance among experts involved in drug reimbursement recommendations: Qualitative evidence from HTA committees in Canada and Poland. <i>Health Policy</i> , 2021, 125, 307-319.	3.0	7

#	ARTICLE	IF	CITATIONS
127	Describing Sources of Uncertainty in Cancer Drug Formulary Priority Setting across Canada. <i>Current Oncology</i> , 2021, 28, 2708-2719.	2.2	7
128	Real-world Safety of Bevacizumab with First-line Combination Chemotherapy in Patients with Metastatic Colorectal Cancer: Population-based Retrospective Cohort Studies in Three Canadian Provinces. <i>Clinical Oncology</i> , 2022, 34, e7-e17.	1.4	7
129	Vaccine nationalism will persist: global public goods need effective engagement of global citizens. <i>Globalization and Health</i> , 2022, 18, 14.	4.9	7
130	Early-Phase Clinical Trials and Reimbursement Submissions to the Pan-Canadian Oncology Drug Review. <i>Pharmacoeconomics</i> , 2021, 39, 373-377.	3.3	6
131	Women's acceptability of and experience with primary human papillomavirus testing for cervix screening: HPV FOCAL trial cross-sectional online survey results. <i>BMJ Open</i> , 2021, 11, e052084.	1.9	6
132	Quality of End-of-Life Cancer Care in Canada: A 12-Year Retrospective Analysis of Three Provinces' Administrative Health Care Data Evaluating Changes over Time. <i>Current Oncology</i> , 2021, 28, 4673-4685.	2.2	6
133	Feasibility, Acceptability, and Clinical Significance of a Dyadic, Web-Based, Psychosocial and Physical Activity Self-Management Program (TEMPO) Tailored to the Needs of Men with Prostate Cancer and Their Caregivers: A Multi-Center Randomized Pilot Trial. <i>Current Oncology</i> , 2022, 29, 785-804.	2.2	6
134	Human papillomavirus-based screening at extended intervals missed fewer cervical precancers than cytology in the HPV For Cervical Cancer (HPV FOCAL) trial. <i>International Journal of Cancer</i> , 2022, 151, 897-905.	5.1	5
135	Cancer Patients' Experiences with Telehealth before and during the COVID-19 Pandemic in British Columbia. <i>Current Oncology</i> , 2022, 29, 4199-4211.	2.2	5
136	COST-EFFECTIVENESS IMPACTS CANCER CARE FUNDING DECISIONS IN BRITISH COLUMBIA, CANADA, EVIDENCE FROM 1998 TO 2008. <i>International Journal of Technology Assessment in Health Care</i> , 2017, 33, 481-486.	0.5	4
137	Cancer drug expenditure in British Columbia and Saskatchewan: a trend analysis. <i>CMAJ Open</i> , 2018, 6, E292-E299.	2.4	4
138	Sociodemographic characteristics of women with invasive cervical cancer in British Columbia, 2004-2013: a descriptive study. <i>CMAJ Open</i> , 2021, 9, E424-E432.	2.4	4
139	Health-related quality of life data collected in chimeric antigen receptor T-cell (CAR-T) therapy clinical trials. <i>Journal of Cancer Policy</i> , 2021, 30, 100304.	1.4	4
140	Experiences and perspectives of individuals accessing CAR-T cell therapy: A qualitative analysis of online Reddit discussions. <i>Journal of Cancer Policy</i> , 2021, 30, 100303.	1.4	4
141	Modes of coordination for health technology adoption: Health Technology Assessment agencies and Group Procurement Organizations in a polycentric regulatory regime. <i>Social Science and Medicine</i> , 2020, 265, 113528.	3.8	4
142	Risk of Anxiety and Depression after Diagnosis of Young-Onset Colorectal Cancer: A Population-Based Cohort Study. <i>Current Oncology</i> , 2022, 29, 3072-3081.	2.2	4
143	"Bring the Hoses to Where the Fire Is": Differential Impacts of Marginalization and Socioeconomic Status on COVID-19 Case Counts and Healthcare Costs. <i>Value in Health</i> , 2022, 25, 1307-1316.	0.3	4
144	How to Control the Costs of Health Care Services – An Inventory of Strategic Options. <i>Healthcare Management Forum</i> , 2009, 22, 23-30.	1.4	3

#	ARTICLE	IF	CITATIONS
145	Improving the Quality of Abstract Reporting for Economic Analyses in Oncology. <i>Current Oncology</i> , 2012, 19, 428-435.	2.2	3
146	Exploring Colposcopists' Attitudes Towards Use of HPV Testing as a Primary Screening Tool for Cervical Cancer in British Columbia. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2013, 35, 657-663.	0.7	3
147	A study protocol for a multicenter randomized pilot trial of a dyadic, tailored, web-based, psychosocial, and physical activity self-management program (TEMPO) for men with prostate cancer and their caregivers. <i>Pilot and Feasibility Studies</i> , 2021, 7, 78.	1.2	3
148	Understanding Contextual Factors in Cost, Quality and Priority Setting Decisions in Health Comment on "Contextual Factors Influencing Cost and Quality Decisions in Health and Care: A Structured Evidence Review and Narrative Synthesis". <i>International Journal of Health Policy and Management</i> , 2018, 7, 1145-1147.	0.9	3
149	Willingness to Self-Collect a Sample for HPV-Based Cervical Cancer Screening in a Well-Screened Cohort: HPV FOCAL Survey Results. <i>Current Oncology</i> , 2022, 29, 3860-3869.	2.2	3
150	Health services research, policy and practice in Australia and New Zealand: a coming of age. <i>Journal of Health Services Research and Policy</i> , 2004, 9, 1-2.	1.7	2
151	Commentary on: Quality-of-Life Effects of Prostate-Specific Antigen Screening. <i>Urology</i> , 2013, 81, 7-8.	1.0	2
152	Comparative Effectiveness Research and Priority Setting. , 2016, , 95-103.		2
153	Economic Evaluation in Adolescent and Young Adult Cancer: Methodological Considerations and the State of the Science. <i>Pediatric Oncology</i> , 2017, , 779-799.	0.5	2
154	Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months: The HPV FOCAL Randomized Clinical Trial. <i>Obstetrical and Gynecological Survey</i> , 2018, 73, 632-634.	0.4	2
155	Impact of a cancer diagnosis on the income of adult cancer survivors: a scoping review protocol. <i>BMJ Open</i> , 2021, 11, e047315.	1.9	2
156	Comparing Childhood Cancer Care Costs in Two Canadian Provinces. <i>Healthcare Policy</i> , 2020, 15, 76-88.	0.6	2
157	Mapping Canadian Data Assets to Generate Real-World Evidence: Lessons Learned from Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration's RWE Data Working Group. <i>Current Oncology</i> , 2022, 29, 2046-2063.	2.2	2
158	The FACT-8D, a new cancer-specific utility algorithm based on the Functional Assessment of Cancer Therapies-General (FACT-G): a Canadian valuation study. <i>Health and Quality of Life Outcomes</i> , 2022, 20, .	2.4	2
159	Pan-Canadian Quality Indicators for Patients at End of Life Derived from interRAI Data. <i>Journal of Pain and Symptom Management</i> , 2018, 56, e59-e60.	1.2	1
160	Quality of life and socioeconomic indicators associated with survival of myeloid leukemias in Canada. <i>EJHaem</i> , 2020, 1, 69-78.	1.0	1
161	Design and implementation of a survey of senior Canadian healthcare decision-makers: Organization-wide resource allocation processes. <i>Health</i> , 2012, 04, 1007-1014.	0.3	1
162	The Girls-Only HPV Vaccination Program in British Columbia, Canada: A Qualitative Study Exploring Expert Informants' Perspectives of Input From the Public. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2017, 39, 726-727.	0.7	0

#	ARTICLE	IF	CITATIONS
163	Benefits of Early Palliative Care in the Community: A Propensity Score Matched Cancer Cohort. <i>Journal of Pain and Symptom Management</i> , 2018, 56, e42.	1.2	0
164	Special Supplement on Canadian Cancer Costing Research. <i>Current Oncology</i> , 2019, 26, 85-86.	2.2	0
165	Disease detection at the 48-month exit round of the HPV FOCAL cervical cancer screening trial in women per-protocol eligible for routine screening. <i>International Journal of Cancer</i> , 2020, 146, 1810-1818.	5.1	0
166	Priority setting methods and cancer control. , 2013, , .		0
167	The Cost-Effectiveness of Clinical Genomic Tests to Aid CR1 Treatment Decisions in Intermediate-Risk AML. <i>Blood</i> , 2014, 124, 2650-2650.	1.4	0
168	Comparative Effectiveness Research and Priority Setting. , 2015, , 1-9.		0
169	Health Utility during the First Two Years of Treatment of Hematological Malignancies. <i>Blood</i> , 2016, 128, 3608-3608.	1.4	0
170	42: Understanding End-of-Life Cancer Care in Canada: an Updated 12-Year Retrospective Analysis of Three Provinces' Administrative Health Care Data. <i>Radiotherapy and Oncology</i> , 2021, 163, S20-S21.	0.6	0
171	Diverse Discussion in Public Deliberation on Cancer Drug Funding. <i>Journal of Deliberative Democracy</i> , 2022, 18, .	0.6	0